TAS1553

TAS1553 is an orally administered, small molecule inhibitor that targets the interaction between the R1 and R2 subunits of ribonucleotide reductase (RNR), a key enzyme required for DNA synthesis. By blocking this protein-protein interaction, TAS1553 prevents assembly and activity of RNR, leading to a reduction in deoxyribonucleotide triphosphate (dNTP) pools necessary for DNA replication. This results in DNA replication stress, reduced dATP levels, and induction of apoptosis in cancer cells. TAS1553 has demonstrated antiproliferative activity in human cancer cell lines and robust antitumor efficacy in preclinical models of both hematological malignancies (such as acute myeloid leukemia) and solid tumors. The drug was developed using high-throughput screening (HTS) and structure-based drug design (SBDD). Clinical development has focused on relapsed/refractory acute myeloid leukemia (AML), high-risk myeloproliferative neoplasms, and myelodysplastic/myeloproliferative diseases[1][4][5][6].